Lifeward enters investment, partnership agreement with Oramed

Lifeward (LFWD) announced that it has entered into a transformative strategic partnership with Oramed Pharmaceuticals (ORMP). The transaction, which has received unanimous approval from Lifeward’s board of directors and is subject to shareholder approval, includes Lifeward integrating Oramed’s proprietary protein oral delivery technology and Oramed acquiring up to a 49.99% equity ownership in Lifeward. The investment structure provides Lifeward with access to up to approximately $47 million of capital through equity, convertible notes, milestone-based funding, and warrant coverage. This capital framework is designed to support Lifeward’s path to profitability while enabling selective investment in high-value innovation. Under a clinical trial management agreement, Oramed will retain responsibility for managing and funding the anticipated POD clinical program. This structure allows Lifeward to maintain operational focus on profitability and cash generation, while retaining exposure to the potential upside of a large-scale biotech opportunity.